Santacruzamate A is primarily studied for its potent biological activity, particularly as a histone deacetylase (HDAC) inhibitor. This property makes it a compound of interest in cancer research, where it has shown potential to induce cell cycle arrest and apoptosis in various tumor cell lines. Its ability to modulate epigenetic pathways suggests utility in developing therapies for hematological and solid malignancies. Additionally, due to its unique structural features and strong inhibitory effects on HDAC enzymes, it serves as a valuable molecular probe for studying chromatin remodeling and gene expression in cellular models. Research remains largely preclinical, focusing on understanding its mechanism of action and optimizing its use in targeted cancer treatments.